Company Overview of REGiMMUNE Corporation
REGiMMUNE Corporation, a biotechnology company, engages in the discovery, development, and commercialization of immune-regulatory therapeutics to treat life-threatening diseases and debilitating disorders. Its products include RGI-2001 for graft versus host disease (GvHD) associated with hematopoietic stem cell transplantation (HSCT) as a proof of concept; and RGI-3010, a immunetolenance inducing liposome encapsulating proinsulin designed to increase the number of regulatory T cells and tolerize the immune system to proinsulin, thereby turning off the self directed immune attack. The company was founded in 2006 and is headquartered in Tokyo, Japan. It has an additional office in Mountain Vie...
Tokyo Industry Trade Center 607 (6th Floor)
Founded in 2006
Key Executives for REGiMMUNE Corporation
Co-Founder, Chief Executive Officer, President and Non-Executive Director
Chief Development Officer and Senior Director
Compensation as of Fiscal Year 2015.
REGiMMUNE Corporation Key Developments
REGiMMUNE Corporation Presents at BIO-Europe 2014, Nov-04-2014 02:45 PM
Sep 3 14
REGiMMUNE Corporation Presents at BIO-Europe 2014, Nov-04-2014 02:45 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.
REGiMMUNE Corporation to Present Its Method for Long-Term Tolerance in Organ Transplantation at World Transplant Congress in San Francisco
Jul 25 14
REGiMMUNE Corporation announced that it will present results from its research on its novel approach to long-term tolerance in organ transplantation without continuous administration of immune suppressants at the World Transplant Congress (WTC) on Tuesday, July 29, 2014. Robust, lifelong, donor-specific tolerance can be reliably achieved by induction of mixed chimerism in various animal models of bone transplantation. To date, the clinical application of these protocols has been impeded by the potential toxicity of the required host conditioning regimens. The REGiMMUNE poster presents the potential of a novel approach using a ligand alpha-GalCer (aGC) for iNKT cells and suboptimal dosage of antibody that blocks CD40:CD40L signaling as a powerful method to generate mixed chimerism. Invariant natural killer T (iNKT) cells are one of the innate lymphocytes that regulate immunity, although it is still elusive how iNKT cells should be manipulated for transplant tolerance. It previously reported that the liposomal formulation of -galactosylceramide (Lipo-aGC) could enhance immune-regulative aspect of iNKT cells compared to the conventional aGC. Here describe a novel approach to induce mixed chimerism (MC) by activating iNKT cells with Lipo-aGC under CD40-CD40L blockade (MR1). 3Gy irradiated BALB/c mice were transplanted with B6 bone marrow cells (BMC s) with/without Lipo-aGC and/or several dosages of MR1. Only combination therapy of Lipo-aGC plus suboptimal-MR1 showed robust MC. Mice established MC completely accepted subsequent cardiac allografts in a donor-specific manner. High amounts of Th2-cytokines were detected right after iNKT-cell activation, while subsequent IFN- production by NK cells was effectively inhibited by MR1. Expansion of regulatory T cells (Tregs) was observed in MC mice and Treg-depletion on 1 day before transplantation resulted MC brake. Further, iNKT-cell knockout mice failed both MC establishment and Tregs expansion. These results collectively suggest that new protocol makes it possible to induce donor-specific tolerance by enhancement of the innate regulatory mechanism in place of the conventional immunosuppression.
REGiMMUNE Corporation Presents at The 21st Annual Future Leaders in the Biotech Industry Conference, Mar-28-2014 03:30 PM
Mar 11 14
REGiMMUNE Corporation Presents at The 21st Annual Future Leaders in the Biotech Industry Conference, Mar-28-2014 03:30 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|